Corvus Pharmaceuticals (CRVS) Enterprise Value (2022 - 2025)
Corvus Pharmaceuticals has reported Enterprise Value over the past 4 years, most recently at -$2.9 million for Q3 2025.
- Quarterly results put Enterprise Value at -$2.9 million for Q3 2025, up 38.74% from a year ago — trailing twelve months through Sep 2025 was -$2.9 million (up 38.74% YoY), and the annual figure for FY2024 was -$52.0 million, down 311.76%.
- Enterprise Value for Q3 2025 was -$2.9 million at Corvus Pharmaceuticals, up from -$14.7 million in the prior quarter.
- Over the last five years, Enterprise Value for CRVS hit a ceiling of -$2.9 million in Q3 2025 and a floor of -$52.0 million in Q4 2024.
- Median Enterprise Value over the past 4 years was -$13.2 million (2022), compared with a mean of -$16.6 million.
- Peak annual rise in Enterprise Value hit 76.72% in 2024, while the deepest fall reached 311.76% in 2024.
- Corvus Pharmaceuticals' Enterprise Value stood at -$13.2 million in 2022, then grew by 4.1% to -$12.6 million in 2023, then tumbled by 311.76% to -$52.0 million in 2024, then skyrocketed by 94.48% to -$2.9 million in 2025.
- The last three reported values for Enterprise Value were -$2.9 million (Q3 2025), -$14.7 million (Q2 2025), and -$5.0 million (Q1 2025) per Business Quant data.